Conjugated estrogens oral - Teva Pharmaceutical Industries

Drug Profile

Conjugated estrogens oral - Teva Pharmaceutical Industries

Alternative Names: Cenestin; Synthetic conjugated estrogens, A

Latest Information Update: 16 Oct 2009

Price : $50

At a glance

  • Originator Duramed Pharmaceuticals Inc
  • Class Estradiol congeners; Hormonal replacements; Osteoporosis therapies
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Atrophic vaginitis; Postmenopausal osteoporosis; Vasomotor symptoms

Most Recent Events

  • 20 Oct 2004 Data presented at the 15th Annual Meeting of the North American Menopause Society (NAMS-2004) have been added to the Women's Health therapeutic trials section
  • 06 May 2004 Cenestin® 0.45mg tablets launched for Menopausal syndrome in USA (PO)
  • 11 Feb 2004 Barr Laboratories has received approval for its sNDA for Cenestin® 0.45mg tablet for the treatment of severe vasomotor symptoms of menopause
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top